|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC:One-year follow-up显示文摘AIM:To evaluate the efficacy and safety of combination therapy with recombinant adenovirus p53 injection (rAdp53) and transcatheter hepatic arterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC).METHODS:A total of 82 patients with advanced HCC treated only with TACE served as control group.Another 68 patients with HCC treated with TACE in combination with recombinant adenovirus-p53 injection served as p53 treatment group.Patients were followed up for 12 mo.Safety and therapeutic effects were evaluated according to the improvement in clinical symptoms,leukocyte count,Karnofsky and RECIST criteria.Survival rate was calculated with Kaplan-Meier method.RESULTS:The total effective rate was 58.3% for p53 treatment group,and 26.5% for control group (P < 0.05).The incidence of gastrointestinal symptoms was lower in p53 treatment group than in control group (P < 0.05).The 3-,6-and 12-mo survival rates were significantly higher for p53 treatment group than for control group (P < 0.01).The combination treatment was well tolerated with such adverse events as fever (51.5%,P=0.006) and pain of muscles and joints (13.2%,P=0.003),which were significantly higher than the chemotherapy.Except for these minor adverse effects,no severe vector-related complications were identified.With respect to the efficacy,patients in p53 treatment group had less gastrointerestinal symptoms (P=0.062),better improvement in tumor-related pain (P=0.003),less downgrade of leukocyte counts (P=0.003) and more upgrade of Karnofsky performance score (P=0.029) than those in control group.The total effective rate (CR + PR) for p53 treatment group and control group was 58.3% and 26.5%,respectively,with distributions of different effect in two groups (P=0.042).The survival rates were 89.71%,76.13%,and 43.30% for p53 treatment group,and 68.15%,36.98%,and 24.02% for control group,respectively,3,6 and 12 mo after treatment,suggesting that the survival rates are significantly higher for p53 treatment group than for control group (P=0.0002).CONCLUSION:The rAd-p53 gene therapy in combination with TACE is a safe and effective treatment modality for advanced HCC. | Yong-Song Guan Yuan Liu Qing He Xiao Li Lin Yang Ying Hu Zi La | 2011 | World Journal of Gastroenterology2011，17，16： | 21 |
| 2 | Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer,one year follow-up显示文摘Objective:In the present study,we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene(rAd-p53) injection in patients with advanced non-small-cell lung cancer(NSCLC) in the combination with the therapy of bronchial arterial infusion(BAI).Methods:A total of 58 patients with advanced NSCLC were enrolled in a non-randomized,two-armed clinical trial.Of which,19 received a combination treatment of BAI and rAd-p53(the combo group),while the remaining 39 were treated with only BAI(the control group).Patients were followed up for 12 months,with safety and local response evaluated by the National Cancer Institute's Common Toxicity Criteria and response evaluation criteria in solid tumor(RECIST),respectively.Time to progression(TTP) and survival rates were also analyzed by Kaplan-Meier method.Results:In the combo group,19 patients received a total of 49 injections of rAd-p53 and 46 times of BAI,respectively,while 39 patients in the control group received a total of 113 times of BAI.The combination treatment was found to have less adverse events such as anorexia,nausea and emesis,pain,and leucopenia(P<0.05) but more arthralgia,fever,influenza-like symptom,and myalgia(P<0.05),compared with the control group.The overall response rates(complete response(CR)+partial response(PR)) were 47.3% and 38.4% for the combo group and the control group,respectively(P>0.05).Patients in the combo group had a longer TTP than those in the control group(a median 7.75 vs 5.5 months,P=0.018).However,the combination treatment did not lead to better survival,with survival rates at 3,6,and 12 months in the combo group being 94.74%,89.47%,and 52.63%,respectively,compared with 92.31%,69.23%,and 38.83% in the control group(P=0.224).Conclusion:Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the quality of life and delayed the disease progression.A further study to better determine the efficacy of this combination therapy is warranted. | Yong-song GUAN Yuan LIU Qing ZOU Qing HE Zi LA Lin YANG Ying HU | 2009 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2009，10，5： | 20 |
| 3 | p53 gene in treatment of hepatic carcinoma:Status quo显示文摘Hepatocellular carcinoma (HCC) is one of the 10 most common cancers worldwide. There is no ideal treatment for HCC yet and many researchers are trying to improve the effects of treatment by changing therapeutic strategies. As the majority of human cancers seem to exhibit either abnormal p53 gene or disrupted p53 gene activation pathways, intervention to restore wild-type p53 (wt-p53) activities is an attractive anti-cancer therapy including HCC. Abnormalities of p53 are also considered a predisposition factor for hepatocarcinogenesis. p53 is frequently mutated in HCC. Most HCCs have defects in the p53-mediated apoptotic pathway although they carry wt-p53. High expression of p53 in vivo may exert therapeutic effects on HCC in two aspects: (1) High expression of exogenous p53 protein induces apoptosis of tumor cells by inhibiting proliferation of cells through several biologic pathways and (2) Exogenous p53 renders HCC more sensitive to some chemotherapeutic agents. Several approaches have been designed for the treatment of HCC via the p53 pathway by restoring the tumor suppression function from inactivation, rescuing the mutated p53 gene from instability, or delivering therapeutic exogenous p53. Products with p53 status as the target have been studied extensively in vitro and in vivo . This review elaborates some therapeutic mechanisms and advances in using recombinant human adenovirus p53 and oncolytic virus products for the treatment of HCC. | Yong-Song Guan Zi La Lin Yang Qing He Ping Li | 2007 | World Journal of Gastroenterology2007，13，7： | 12 |
| 4 | Wavelet analysis in infantilenystagmus syndrome: limitations and abilities显示文摘 | Abel LA Wang ZI Dell ’ Osso LF | 2008 | Invest Oph-thalmol Vis2008，49，8： | 1 |
| 5 | Synthesis, Structure and Magnetic Properties of Novel Carboxylato-bridged Pentanuclear Copper(Ⅱ)-Lanthanoid(Ⅲ) Complexes显示文摘IntroductionPolynuclearmixed-metalcomplexescontainingbothtransitionandlanthanoidmetalionsareofspecialcurentinterestinrelation... | TONG Ming liang, WU Yu luan and CHEN Xiao ming ** (Department of Chemistry, Zhongshan University, Guangzhou, 510275) SUN Zi ming and David N. Hendrickson ** (Department of Chemistry 0358, University of California at San Diego, La Jol | 1998 | Chemical Research in Chinese Universities1998，14，3： | 1 |
| 6 | TRAF3交互蛋白2介导雄性小鼠肥胖相关血管胰岛素抵抗与功能异常显示文摘血管胰岛素抵抗是肥胖的一个特点,可导致血管异常与疾病的发生。然而,目前对肥胖相关的血管胰岛素抵抗及功能异常的潜在分子机制仍了解很少。该文假设TRAF3交互蛋白2(TRAF3 interacting protein 2,TRAF3IP2),一个已知在心血管病激活病理应激通路的促炎症接头分子,与肥胖相关的血管胰岛素抵抗与功能异常有因果联系。研究人员通过体外在内皮细胞、离体动脉中,体内在喂食诱发肥胖的TRAF3IP2敲除小鼠模型中进行基因调控. | 赵狄(摘译) 刘莉(审校) Grunewald ZI Ramirez-Perez FI Woodford ML Morales-Quinones M Mejia S Manrique-Acevedo C Siebenlist U Martinez-Lemus LA Chandrasekar B Padilla J | 2020 | 中华高血压杂志2020，28，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员